Xenon Pharmaceuticals (NASDAQ:XENE) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Free Report) in a report released on Tuesday, Benzinga reports. The firm currently has a $58.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts also recently issued research reports about the company. StockNews.com initiated coverage on Xenon Pharmaceuticals in […]

Related Keywords

Canada ,Simonn Pimstone ,Stifel Nicolaus ,Xenon Pharmaceuticals ,Wells Fargo Company ,News Ratings For Xenon Pharmaceuticals Daily ,Institutional Trading Of Xenon Pharmaceuticals ,Cantor Fitzgerald ,Advisors Asset Management Inc ,Needham Company ,Analyst Recommendations For Xenon Pharmaceuticals ,Xenon Pharmaceuticals Trading Down ,Securities Exchange Commission ,Jpmorgan Chase Co ,Xenon Pharmaceuticals Inc ,Free Report ,Moderate Buy ,Pharmaceuticals Trading Down ,Get Free Report ,Director Dawn Svoronos ,Exchange Commission ,Director Simon ,Advisors Asset Management ,Pharmaceuticals Inc ,Xenon Pharmaceuticals Daily ,Nasdaq Xene ,Exene ,Medical ,Reiterated Rating ,